Navigation Links
Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
Date:12/22/2010

ition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi), (vii)

About BYETTA® (exenatide) injection

BYETTA was the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not currently recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been studied in people who have pancreatitis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a TZD, with potential weight loss (BYETTA is not a weight-loss product). BYETTA was approved in April 2005 and has been used by more than 1.3 million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on post-marketing data, BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have seve
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
2. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
3. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
4. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
5. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
6. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
7. Amylin Pharmaceuticals to Webcast Third Quarter Results
8. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
9. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
11. Amylin Pharmaceuticals to Webcast Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 According to a ... Growth, Trends & Forecasts (2015-2020), , published by Mordor Intelligence, ... billion by the end of 2020, with North ... more than 40% of the global market size. The Global ... CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announces the launch of their 2nd generation cell therapy POD® design. The 2nd ... but it also represents a new POD® design. , “G-CON first offered ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... June 11 MedNet Solutions, a global life sciences ... will unveil a variety of exciting new and enhanced ... Annual Meeting, June 22-24, 2009, in San Diego, CA. ... its market-leading electronic data capture/eClinical tool set to improve ...
... ... how Earned Value Management can improve control over clinical development costs, payments, and accruals ... , ... (PRWEB) June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical ...
... (Nasdaq: MDVN ) today ... CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial ... Alzheimer,s disease. , , The international, double-blind, ... the enrollment target of 525 patients. More than 40 ...
Cached Biology Technology:MedNet Solutions to Introduce New EDC/eClinical Technologies at the 2009 Drug Information Association Annual Meeting 2ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... vibrant insects, with colorations sometimes designed to deflect predators. ... defenses may be driven by enemies one-tenth their size. ... researchers have believed large predators like birds mainly influenced ... behavioral study to directly test the defense mechanism of ...
... be it heat or electricity, has to be used right ... its transportation can be rather complicated. Creating solar cells capable ... that is to say fuel, is therefore the future challenge ... are working on a catalyst that imitates and improves what ...
... amino acids in order to conduct electricity, according to a ... open-access journal of the American Society for Microbiology, on Tuesday, ... sulfurreducens uses these nanowires, called pili, to transport electrons ... of these wires can also be harnessed by humans for ...
Cached Biology News:UF study shows spiders, not birds, may drive evolution of some butterflies 2UF study shows spiders, not birds, may drive evolution of some butterflies 3Catalysts that produce 'green' fuel 2Biological wires carry electricity thanks to special amino acids 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Biology Products: